Accelerating development of high-risk neuroblastoma patient-derived xenograft models for preclinical testing and personalised therapy

Alvin Kamili, Andrew J. Gifford, Nancy Li, Chelsea Mayoh, Shu-Oi Chow, Timothy W. Failes, Georgina L. Eden, Roxanne Cadiz, Jinhan Xie, Robyn E. Lukeis, Murray Norris, Michelle Haber, Geoffrey B. McCowage, Greg M. Arndt, Toby N. Trahair and Jamie I. Fletcher

BACKGROUND: Predictive preclinical models play an important role in the assessment of new treatment strategies and as avatar models for personalised medicine; however, reliable and timely model generation is challenging. We investigated the feasibility of establishing patient-derived xenograft (PDX) models of high-risk neuroblastoma from a range of tumour-bearing patient materials and assessed approaches to improve engraftment efficiency.

METHODS: PDX model development was attempted in NSG mice by using tumour materials from 12 patients, including primary and metastatic solid tumour samples, bone marrow, pleural fluid and residual cells from cytogenetic analysis. Subcutaneous, intramuscular and orthotopic engraftment were directly compared for three patients.

RESULTS: PDX models were established for 44% (4/9) of patients at diagnosis and 100% (5/5) at relapse. In one case, attempted engraftment from pleural fluid resulted in an EBV-associated atypical lymphoid proliferation. Xenogeneic graft versus host disease was observed with attempted engraftment from lymph node and bone marrow tumour samples but could be prevented by T-cell depletion. Orthotopic engraftment was more efficient than subcutaneous or intramuscular engraftment.

CONCLUSIONS: High-risk neuroblastoma PDX models can be reliably established from diverse sample types. Orthotopic implantation allows more rapid model development, increasing the likelihood of developing an avatar model within a clinically useful timeframe.

British Journal of Cancer (2020) 122:680–691; https://doi.org/10.1038/s41416-019-0682-4
been described in more recent accounts.\textsuperscript{22-28} Herein, we demonstrate the feasibility of developing high-risk neuroblastoma PDX models at a high success rate from multiple sources of tumour-bearing patient materials at both diagnosis and relapse and from primary and metastatic tumour sites, and for the first time, residual tumour cells from cytogenetic analysis. We also show that the engraftment time is influenced not only by the number of tumour cells inoculated but also by the site of inoculation, with orthotopic (adrenal) engraftment allowing more rapid model generation than subcutaneous engraftment. Finally, we also describe some of the challenges in developing PDX models—the development of xenogenic graft versus host disease in recipient mice and the proliferation of Epstein-Barr virus (EBV)-infected cells rather than tumour cells—and provide strategies for obviating these hurdles.

METHODS

Patient samples and processing

Fresh tumour specimens were obtained from patients at the Sydney Children’s Hospital Network (SCHN) under approval by the SCHN Human Research Ethics Committee (LNR/14/SCHN/392, LNR/14/SCHN/497). The primary purpose for developing the PDX models was to establish and improve xenografting approaches, to develop models to enable future preclinical testing, including in the context of personalised medicine. The relapse samples were from patients enrolled in a pilot feasibility study (TARGET) for a subsequent personalised medicine clinical trial (PRISM; Clinical-Trials.gov Identifier NCT0336931), however without intention to return data to the treating clinician. Informed parental or guardian consent was obtained for each patient. The initial diagnosis of neuroblastoma was confirmed for each patient by a consultant paediatric pathologist. Samples were collected and transported in L-15 medium (Life Technologies, Carlsbad, CA, USA) at room temperature within 2–8 h after surgery. Solid tumour sample dissociation was performed enzymatically using a human tumour dissociation kit and a GentleMACS dissociator (Miltenyi Biotec, Bergisch Gladbach, Germany) into a single-cell suspension. Smaller samples were engraved as 2–5-mm fragments. Bone marrow samples were collected in EDTA tubes and mononuclear cells isolated by Ficoll separation. Depletion of T lymphocytes was performed with human CD3 microbeads and an autoMACS Pro (Miltenyi Biotec) prior to assessment by flow cytometry and the CD3-negative population used for inoculation. Cells from pleural fluid were isolated by centrifugation and washed with red blood cell lysis buffer prior to inoculation. Cells from cytogenetics culture were obtained after completion of diagnostic analyses, harvested in EDTA-trypsin and washed in PBS prior to inoculation.

Establishment of PDX models

All animal studies were performed in accordance with the guidelines approved by the University of New South Wales Animal Care and Ethics Committee (ACEC 17/101B) and the requirements of the Australian Code for the Care and Use of Animals for Scientific Purposes. Animals were housed in a specific pathogen-free environment in Techniplast research animal cages with filter tops and floor area of 400 cm\(^2\) with 2–6 mice/cage, and under 12:12 light/dark cycles. Bedding, enviro dry and igloos were provided for environmental enrichment. Irradiated rat and mouse breeder cages and water were provided ad libitum. All animal procedures were performed inside a biosafety cabinet under sterile conditions during the animal’s light time cycle. Dissociated tumour cells, bone marrow, pleural fluid and cytogenetic cells (0.1–10 million cells) were mixed in RPMI (Life Technologies) and growth factor-reduced Matrigel (Corning Inc., Corning, NY, USA) at equal volume ratio and implanted subcutaneously using a 27-gauge needle (Terumo, Tokyo, Japan) into the flank of female NOD.Cg-Pkdcrd\textsuperscript{+/−}Il2rg\textsuperscript{−/−}/SzJ (NSG) mice\textsuperscript{29} obtained from Australian Bioresources (Moss Vale, NSW, Australia).

For implantation of tumour fragments, mice were anaesthetised using a Stinger anaesthetic machine (DarvallVet, Gladesville, NSW, Australia) with 2–2.5% isoflurane (Isothesia, Henry Schein, Melville, NY, USA) and 800 mL/min oxygen. A 5-mm horizontal incision was made on the dorsum of the mice, 10 mm rostral to the base of the tail, to create a subcutaneous pocket. A 2–5-mm fragment of tumour dipped in growth factor-reduced Matrigel was inserted and the incision site was closed with a wound clip. Buprenorphine (0.1 mg/kg, intraperitoneal) (Provet, Castle Hill, Australia) was administered for analgesia. Tumour growth was measured by Vernier callipers at least twice a week. Mice were euthanised once tumour size reached 1000 mm\(^3\), calculated using the formula: Length × Width × Height/2, by CO\(_2\) overdose followed by cervical dislocation. Tumours were triaged for histological and molecular analyses, cryopreservation and expansion in secondary recipient mice. Failure to engraft was defined as no measurable tumour at maximum holding time (12 months) and was confirmed by necropsy.

Engraftment site comparison

For each of three patients, a single tumour sample was dissociated and inoculated simultaneously into randomised cohorts of NSG mice at subcutaneous, intramuscular or orthotopic sites. A fixed cell number per mouse was used for each inoculation based on sample availability (5 × 10\(^5\), 1 × 10\(^6\) and 1.35 × 10\(^6\) cells per mouse for A6580, A6912 and A7560, respectively). Subcutaneous inoculation, as well as anaesthesia and analgesia for intramuscular and orthotopic engraftment were performed as described above. For intramuscular engraftment, a 10-mm midline dorsal skin incision was made, 15 mm rostral to the base of the tail.\textsuperscript{30} Cells suspended in a mixture of 10 μL of RPMI and 10 μL of Matrigel were injected into the paraspinal muscle and the incision closed with 9-mm wound clips (Fine Scientific Tools, North Vancouver, BC, Canada). Orthotopic (adrenal) engraftment was performed as previously described.\textsuperscript{31} Briefly, a 15-mm skin incision was made adjacent to the caudal border of the spleen and the superior tip of the left kidney, followed by a 10-mm incision into the abdominal wall to expose the left adrenal gland. Cells suspended in a mixture of 10 μL of RPMI and 10 μL of Matrigel were injected into the fat pad surrounding the left adrenal gland. The abdominal wall was closed with a polyglandin-coated Vilet absorbable suture (Riverpoint Medical, Portland, OR, USA) and the skin incision was closed with wound clips. Mice were monitored daily for 7 days post surgery, and wound clips removed on day 7 post surgery. Intramuscular engraftment was assessed as described above. Orthotopic tumours were assessed by weekly ultrasound imaging and with callipers upon killing to confirm imaging-based measurement. Mice were euthanised by CO\(_2\) overdose followed by cervical dislocation. Event-free survival (EFS) was determined as described previously.\textsuperscript{32}

Ultrasound imaging

Mice were depilated (~10 cm\(^2\)) adjacent to the left adrenal gland and prewarmed Aquasonics Clear Ultrasound Transmission Gel (Parker Laboratories, Fairlawn, NJ, USA) was applied to the area. Imaging was performed using VisualSonics Vevo 2100 (VisualSonics, Toronto, Canada). A linear-array transducer (MS-250) traversed the selected area, acquiring 2D images at ~100-μm intervals, which were reconstructed as a 3D image in a dynamic cube format and analysed using Vevo Lab 1.7.0 software (VisualSonics). Tumour boundaries were manually outlined in parallel slices within the 3D image and the final tumour volume calculated as the sum of the outlined tumour boundary for each slice.

Histology and immunohistochemistry

Tumours and organs were fixed in formalin, embedded in paraffin and then sectioned and stained for histopathologic assessment by a practicing paediatric pathologist (AJG). Stains included
For two patients, both diagnosis and relapse samples were obtained. For three patients, multiple sample types were obtained. Samples (19 in total) included primary solid tumour, intracranial, liver, lymph node and bone marrow metastases, peripheral blood and pleural fluid, in addition to residual cells from cytogenetics analysis (Table 1). PDX models were successfully established for 4 of 9 patients (44%) at diagnosis and 5 of 5 patients (100%) at relapse. On per-sample basis, engraftment rates were 4 of 13 samples (31%) at diagnosis and 6 of 6 samples (100%) at relapse. For the ten samples that were successfully engrafted, the mean time to 1000-mm² tumour was 107 days (range 33–210 days). For the remaining samples, there was no evidence of engraftment after 12 months. The established models represented a wide patient age range at the time of diagnosis (0.3–7.5 years) and were derived from both MYCN-amplified and non-amplified samples. Engraftment at diagnosis was associated with poor outcome (P = 0.048, Fisher’s exact test, Supplementary Table S1). Notably, in three of four cases where engraftment was successful at diagnosis, the patient subsequently relapsed or progressed and died of disease. For two of these patients, a model was also established at relapse: CCI-NB01-DMC and CCI-NB01-RMT from A6698 and CCI-NB02-DMB and CCI-NB02-RPT from A6912. Establishment of models from residual cytogenetics cultures was successful in all four cases. In two of these cases, other tumour material from the same patient inoculated in parallel failed to engraft, while in one case no other sample was available. In the single example (A6580) where a model was generated by direct engraftment (CCI-NB06-RMT) and via cytogenetics culture (CCI-NB06-RMC), the engraftment time was similar (72 and 88 days, respectively). Each of the established models can be serially passaged and the growth time of xenografts from inoculation to 1000 mm² in the secondary passage is shown in Supplementary Table S2.

Characterisation of high-risk neuroblastoma PDX models
Each of the established PDX models was authenticated as being derived from the donor tumour specimen by STR profiling. In each case, the match was 100% across the 18 amplified loci. Morphologically, all ten established subcutaneous xenografts recapitulated the features of the patient tumours from which they were derived (Supplementary Table S3). Each PDX showed features of poorly differentiated neuroblastoma, being composed of neuroblasts and variable amounts of neuropil while lacking overt ganglionic differentiation and Schwannian stroma (Fig. 1a, b, centre and right panels). They were variably positive for commonly used neuroblastoma diagnostic markers NB84 and CD56 (Fig. 1a, b, right panels), and synaptophysin (not shown). PHOX2B immunohistochemical staining was performed on some xenografts, and with one exception (CCI-NB06-RMC, from A6580) showed nuclear positivity in tumour cells (Supplementary Table S3). Retrospective staining of the A6580 donor tumour, an intracranial metastasis, confirmed the absence of PHOX2B staining.

To determine the extent to which each PDX model maintained the key genetic features of the donor tumour material from which it was derived, high-density SNP array was conducted for each PDX-tumour pair. For the majority of models, copy-number variation in the PDX was highly correlated with that of the patient tumour, as assessed by Pearson’s correlation analysis (Table 1). Correlations were higher for relapse models (r = 0.84–0.99) than for diagnosis models (r = 0.035–0.82). The PDX models generally preserved the established prognostic molecular markers and recurrent aberrations observed in the original tumour, including chromosome 1p loss and 17q gain, MYCN and ALK amplification and loss of PHOX2B, TP53, NF1 and ATRX (Fig. 1c and Supplementary Fig. S1A, B). One diagnosis model (CCI-NB04-DML), derived from patient A7167, was substantially divergent from the donor lymph node metastasis sample (r = 0.035), despite confirmation of sample identity by STR profiling (100% match) and
Histologic features that were consistent with high-risk neuroblastoma. Interrogation of a previous SNP array (Affymetrix Cytoscan 750K array) conducted on this patient sample for clinical care revealed that MYCN amplification and the major chromosomal losses (1p, 10q) and gains (1q, 2p, 13q and 17q), were all present in a tumour population that comprised 50% of cells (Supplementary Fig. S1A, C).

Of particular note, two PDX models were established in parallel from patient A6580 (Fig. 2c, Supplementary Table S4) and patient A6912 (Fig. 2d, Supplementary Table S4), xenografted tumours at different tumour volume measurement approaches, tumour volumes for all orthotopic xenografts were also obtained at another (A6912). To exclude the possibility of bias based on subcutaneous engraftment or had not reached the event (1000-mm³ tumour) after 230 days. Intramuscular engraftment was faster than subcutaneous engraftment in one model (A6580), but slower in another (A6912). To exclude the possibility of bias based on different tumour volume measurement approaches, tumour volumes for all orthotopic xenografts were also obtained at endpoint by using callipers and compared with ultrasound analysis. The two measurement approaches yielded equivalent tumour volumes (Supplementary Fig. S3). The morphologic analysis confirmed that all xenografts exhibited features of poorly differentiated neuroblastoma, consistent with the patient tumours

Orthotopic inoculation shortens engraftment time and increases engraftment success rate

Despite the high success rate for subcutaneous engraftment of relapse samples, the success rate for diagnosis samples was below 50%, and the relatively long engraftment time poses a barrier to the use of these models in personalised oncology. To determine whether engraftment at alternative anatomical sites could increase engraftment efficiency, tumour cells from three neuroblastoma patients (A6580, A6912 and A7056) were simultaneously inoculated into three cohorts of mice, subcutaneously, intramuscularly or orthotopically (adrenal gland), and monitored for engraftment and tumour growth. In each case, the tumour sample was already known to engraft (Table 1) and was inoculated at 20–100-fold lower cell number than the previously successful subcutaneous engraftment.

For all three patient tumour samples, orthotopic implantation resulted in the quickest time to measurable engraftment and the shortest median survival time (Supplementary Fig. S2, Fig. 2a). Furthermore, all orthotypically inoculated tumours successfully engrafted, while multiple animals in the intramuscular (A7056) and subcutaneous (A6580 and A7056) groups had no evidence of engraftment or had not reached the event (1000-mm³ tumour) after 230 days. Intramuscular engraftment was faster than subcutaneous engraftment in one model (A6580), but slower in another (A6912). To exclude the possibility of bias based on different tumour volume measurement approaches, tumour volumes for all orthotopic xenografts were also obtained at endpoint by using callipers and compared with ultrasound analysis. The two measurement approaches yielded equivalent tumour volumes (Supplementary Fig. S3). The morphologic analysis confirmed that all xenografts exhibited features of poorly differentiated neuroblastoma, consistent with the patient tumours (Fig. 2b). Skeletal muscle was also observed on the xenograft periphery when the tumour cells were inoculated intramuscularly.

To determine whether chromosomal aberrations present in the original tumour are maintained in the PDX models, irrespective of the engraftment site, high-density SNP array was employed. For both patient A6580 (Fig. 2c, Supplementary Table S4) and patient A6912 (Fig. 2d, Supplementary Table S4), xenografted tumours at...
Fig. 1  Comparison of patient-derived xenograft models and their originating tumours. **a** Representative morphology comparison between primary tumour specimens and subcutaneous PDX models of patient A6698/CCI-NB01-DMC and **b** patient A6912/CCI-NB02-DMB. In both models, H&E staining shows that cell morphology was maintained during establishment (magnification: ×600). Immunohistochemical staining for markers NB84 and CD56 in PDX tumours recapitulates original patient tumours, confirming the diagnosis of poorly differentiated neuroblastoma (magnification: ×400). **c** Representative comparison of copy-number profiles across the genome in A6580 patient tumour and the corresponding PDX models developed from primary biopsy (CCI-NB06-RMT) and cytogenetic residual cells (CCI-NB06-RMC). Regions of copy-number gain are shown in red and regions of copy-number loss in blue. Chromosomes are arranged sequentially, where chromosomal positions are indicated below, and the relative positions of genes commonly aberrant in high-risk neuroblastoma (MYCN, ALK, PHOX2B, MYC, NF1 and ATRX) are indicated above.
Inoculation site | Median survival (days) | P value (vs. subcutaneous) | Median survival (days) | P value (vs. subcutaneous) | Median survival (days) | P value (vs. subcutaneous)
--- | --- | --- | --- | --- | --- | ---
Subcutaneous | 200 | — | 50 | — | > 230 | —
Intramuscular | 136 | 0.0031 | 57 | 0.0981 | > 230 | 0.1385
Orthotopic | 124 | 0.0011 | 41 | 0.0011 | 135 | 0.0011

Fig. 2 Orthotopic implantation accelerates patient samples engraftment. a Kaplan–Meier survival curve of mice engrafted with primary tumour cells from patients A6580, A6912 (relapse) and A7056 at subcutaneous, intramuscular and orthotopic sites. b Representative H&E images of patient tumours and the corresponding PDX tumours from the respective inoculation sites. Image magnification: ×600. c Copy-number variation analysis for A6580 and d A6912 patient samples and PDX models established at each site. Regions of copy-number gain are shown in red and regions of copy-number loss in blue. Chromosomes are arranged sequentially, where chromosomal positions are indicated below, and the relative positions of genes commonly aberrant in high-risk neuroblastoma (MYCN, ALK, PHOX2B, MYC, NF1 and ATRX) are indicated above.
Each site were highly correlated with the patient sample, including conservation of MYCN and ALK amplification, chromosome 1p loss and chromosome 17q gain in each. Minor differences observed between the A6580 patient sample and the PDX tumours included chromosome 1p loss and 18q gain in the subcutaneous and orthotopic models, while differences observed between the A6912 patient sample and the PDX tumours included a region of copy-number loss in chromosome 7q in the subcutaneous model and a region of copy-number gain in chromosome 9p in the intramuscular model. The orthotopic xenograft for patient A7056 was also highly correlated with the patient sample (Supplementary Fig. 4, Supplementary Table S4). Overall, engraftment site had little impact on tumour copy-number aberrations, with orthotopic and intramuscular xenografts being as representative of the donor tumour as subcutaneous xenografts.

T-lymphocyte depletion circumvents xenogeneic graft versus host disease

The engraftment of two patient samples containing a substantial lymphocyte population (A7167, lymph node metastasis, and A5723, bone marrow metastasis) led to alopecia and reddening of skin around the ears and eyes in the recipient mice, consistent with xenogeneic graft versus host disease (GvHD). Postmortem histopathological analysis of the liver from mice inoculated with each sample was also consistent with GvHD (Fig. 3a). Mild effacement of liver architecture with expansion of portal tracts by

![Images and graphs related to the text, including histological staining and flow cytometry data.]
infiltrating activated lymphocytes and occasional neutrophils was observed for both samples. Occasional lymphocytes were seen in close proximity to endothelial cells of the portal vein branches. Expansion of the tunica intima/media of some portal vein branches was seen, accompanied by lymphocytic infiltration of the endothelium (phlebitis) and subjacent connective tissue. The portal lymphocytic infiltrate extended into the adjacent hepatic lobule and was accompanied by necrosis of occasional hepatocytes (acidophil bodies). The mononuclear cell infiltrate was positive for human CD45 and human CD3, and CD19+ B lymphocytes were absent from the liver of A7167-inoculated mice based on CD20 staining, but were present in the liver of mice inoculated with material from patient A5723. Staining for the macrophage marker CD68 was negative. Alternative infectious causes of liver injury were excluded by testing of the animal facility for Helicobacter or norovirus infection and the absence of Helicobacter organisms in the hepatic tissue. There was no evidence of metastatic neuroblastoma to the liver in either case.

Flow cytometric analysis of mononuclear cells isolated from liver and spleen of the mice indicated 55% and 36% CD45-positive human leucocytes in the A7167 mouse liver and spleen, respectively, and 95% CD45-positive human leucocytes in the A5723 mouse liver (Fig. 3b). To preclude the development of xenogeneic GVHD, in subsequent engraftment experiments, patient lymph node or bone marrow samples were subjected to magnetic bead separation to deplete CD3-positive human T lymphocytes prior to engraftment. For patient A6912 (bone marrow metastatic disease), human T lymphocytes were reduced from 16% to less than 1% in post separation (Fig. 3c). This sample subsequently engrafted within 96 days (Table 1, CCI-NB02-DMB), with no signs of xenogeneic GVHD.

Development of EBV-associated atypical B-lymphoid proliferation from a pleural fluid sample

An attempt to generate a xenograft model from a pleural fluid specimen (patient A7012) containing both metastatic neuroblastoma cells and inflammatory cells, including small lymphocytes and neutrophils (Fig. 4a), produced a tumour mass that failed to recapitulate human neuroblastoma. This xenograft comprised an infiltrate of large cells with variably atypical nuclei and ample vacuolated to the eosinophilic cytoplasm. An accompanying patchy inflammatory cell infiltrate was also seen, including apparent lymphocytes and neutrophils. This xenograft was positive for the B-lineage marker CD20 and negative for the neuroblastoma markers PHOX2B and NB84, and negative for the T-cell marker CD3 (Fig. 4b). Additional flow cytometry analysis demonstrated the presence of a CD19-positive B-lymphocyte population (Supplementary Fig. S5); however, clonality studies were not performed. Strong nuclear positivity for EBER-ISH staining (Fig. 4b) and CD20 positivity confirms this tumour as an EBV-associated atypical B-lymphoid proliferation. In contrast, a PDX model established for patient A7012 from cytogenetic residual cells (CCI-NB03-DPC) showed features of poorly differentiated neuroblastoma consistent with the original tumour, NB84 and PHOX2B positivity (Fig. 4c), and strongly correlated with the patient material by SNP array (Supplementary Fig. S1, r = 0.71). Comparative high-throughput drug screening of neuroblastoma patients and PDX-derived cells

To further assess the biological similarly of primary patient cells and those expanded via mouse engraftment, a high-throughput screen of 165 anticancer drugs was performed on dissociated cells from both the A6580 patient sample and the first passage of the cognate PDX (CCI-NB06-RMT) under identical conditions (Fig. 5a). Prior to screening, the PDX cells were analysed for GD2 positivity by flow cytometry to determine neuroblastoma cell content and were found to be 96.6% GD2-positive (Supplementary Fig. S6). The drug library consists of clinically approved chemotherapies and targeted agents, and also experimental anticancer agents currently under investigation. Overall, cells derived from both the initial patient material and PDXs showed highly similar sensitivity to chemotherapeutic agents. The AUC values for all tested drugs in patient cells were highly correlated with those in the PDX cells (r = 0.9018, P < 0.0001, Fig. 5b), suggesting that neuroblastoma tumour cells expanded as xenografts may be fit-for-purpose for personalised drug sensitivity testing.

DISCUSSION

PDX models are known to preserve many of the key biological properties of the tumours from which they were derived and remain stable across passages. These models are predictive of clinical outcomes and therefore are an excellent platform for preclinical drug testing and as avatars for personalised medicine. This study extends previous neuroblastoma PDX model establishment reports by demonstrating that PDX models can also be developed from diagnostic cytogenetic culture without additional loss of fidelity, that more rapid engraftment can be achieved with orthoptic implantation and that additional sample processing can circumvent loss of models by xenogeneic GvHD.

Our subcutaneous engraftment success rates of 44% (4 of 9) for diagnosis patients and 100% (5 of 5) for relapse patients compare favourably with a recent report in which neuroblastoma samples were engrafted para-adrenally with a success rate of 24% at diagnosis (9 of 39) and 33% at relapse (1 of 3). Several factors might contribute to the variation of engraftment rate between these studies, including the source of patient material, time to engraftment, number of cells inoculated and engraftment technique. In an earlier study, the subcutaneous engraftment rate of PDX from neuroblastoma patients at the time of diagnosis was 34% (20 of 58) for all patients attempted, and 45% (15 of 33) from INSS stage IV disease, which is similar to the current study. We found that histologic and molecular features are generally preserved in high-risk neuroblastoma PDX models commensurate with previous reports. The high success rate for samples from cytogenetics culture by comparison with samples from other patient sources that failed to engraft, strongly suggests that these materials should be accessed for model development where possible. While one PDX model (CCI-NB04-DML from A7167) developed from a lymph node metastasis via cytogenetics showed very poor correlation with the originating tumour material based on the CNV profile, further analysis of a clinical SNP array for these samples suggests clonal selection in the PDX, and good concordance with the expanded clone in the original patient material. More generally, evolution and copy-number alteration that occurs during development of PDX models might provide explanation for other differences.

With further optimisation, other potential samples, such as pleural fluid and lymph node metastasis biopsy, can be used as valuable resources for PDX development, increasing engraftment success rate per patient, an essential advance for implementing personalised treatment in this childhood malignancy. Avoiding the loss of engrafted samples due to mouse pathologies is also critical for reliable model development and judicious choice of recipient mice and sample-processing approaches is essential. Highly immune-deficient NSG mice are advantageous for tumour engraftment, have significantly longer life spans than other scid mutant strains and do not develop spontaneous thymoma, which are important considerations when engraftment time is long, as is frequently the case for neuroblastoma models. While the absence of functional NK cells renders NSG mice highly susceptible to xenogeneic GVHD development, we show that this can be avoided by T-lymphocyte depletion of the patient sample.
Development of EBV-associated atypical B-lymphoma proliferation or EBV-related B-cell lymphoma has been previously described after attempted xenografting of other human tumour types in immune-deficient mice and the incidence rate in NSG mice has been reported to be as high as 32%. In healthy individuals, EBV infection is benign with reactivation and subsequent proliferation of EBV-infected lymphocytes suppressed by immune detection and response, whereas in an immune-deficient patient, EBV can transform B cells into the growth phase and trigger the lymphoproliferative disease. Similarly, the lack of immunosurveillance in recipient mice allows the proliferation of the EBV-infected lymphocytes contained in the patient.

PCR-based detection of the EBV BamHI W region, a major internal repeat in EBV genome, in the patient specimen to be engrafted, has been reported to correlate with EBV-related lymphoid proliferation in the derivative PDX and may allow identification of samples requiring lymphocyte depletion. Alternatively, atypical lymphoid proliferations might be obviated by administration of rituximab, an anti-CD20 antibody, as the rate of lymphoma incidence in ovarian cancer PDX models has been reported to decline from 11.1 to 1.88% after the addition of rituximab. Aside from prevention, a robust approach to identify atypical lymphoid proliferation is essential to maintaining xenograft validity and mandatory prior to additional clinical assays, such as drug screening, being performed on the xenograft material.

A major challenge for the use of high-risk neuroblastoma PDX models in personalised medicine is the development, validation and application of models in a timeframe that can still inform individual patient treatment. Approaches that shorten engraftment time or increase engraftment success rates without compromising model fidelity are essential to make this approach
broadly applicable. Our observation that for each of three patient samples, orthotopic adrenal engraftment was substantially faster than either subcutaneous or intramuscular engraftment suggests one approach to reducing engraftment time. The reasons for more rapid adrenal engraftment are not clear; however, the adrenal gland is the most common site of origin for primary neuroblastoma. Alternatively, previous studies have suggested that non-subcutaneous sites may provide greater protection of the engrafted cells against hypothermic insult,\textsuperscript{30} or a greater capacity for angiogenesis.\textsuperscript{22,25,31} While enabling a shorter engraftment time, orthotopic inoculation is more technically challenging than subcutaneous inoculation and animal monitoring typically requires in vivo imaging,\textsuperscript{47,48} which can be particularly labour intensive for the frequent monitoring required in preclinical testing.\textsuperscript{32,48} Our observations that orthotopic, intramuscular and subcutaneous xenografts are equally representative of the donor tumour suggest that engraftment approaches can be selected based on utility.

In addition to in vivo preclinical testing, limited patient material expanded as a PDX model can be used as a primary short-term culture for high-throughput ex vivo testing of drug sensitivity, including for combination chemotherapy.\textsuperscript{77,78} This study demonstrated that PDX-derived cells were dependable alternatives for screening high-risk neuroblastoma, with ex vivo drug sensitivity of primary patient cells and PDX-expanded material being highly correlated.

In summary, we identify dependable engraftment approaches that increase the likelihood of developing informative preclinical models for individual high-risk neuroblastoma patients within a clinically relevant timeframe and reliably expand limited patient material for ex vivo and in vivo drug testing.

ACKNOWLEDGEMENTS

The authors thank the patients, clinicians and researchers of the Sydney Children’s Hospital Network, the Sydney Children’s Tumour Bank Network and the Zero Childhood Cancer initiative for providing samples and related clinical information, Professor C. Patrick Reynolds (Texas Tech University Health Sciences Center and Children’s Oncology Group Childhood Cancer Repository) for technical advice, the Biological Resources Imaging Laboratory within the Mark Wainwright Analytical Centre at the University of New South Wales for ultrasound imaging support and Ms Josiane Demetriou for acting as the consumer representative for this study. Children’s Cancer Institute Australia is affiliated with University of New South Wales and the Sydney Children’s Hospital Network.

AUTHOR CONTRIBUTIONS

J.I.F. and T.N.T. conceived and supervised the project. A.K. processed patient samples, established the PDX models and wrote the paper with contributions from J.I.F., T.N.T.
and A.J.G. A.J.G. performed histopathology validation of PDx models and generated immunohistochemistry images. N.L., G.L.E., R.C. and J.X. performed animal works, ultrasound measurement and flow cytometry. C.M. analysed SNP array data. S.C., T.W.F. and G.M.A. performed ex vivo high-throughput screening and data analysis. R.E.L. provided patient cytogenetics residual cells. T.N.T. and G.B.M. were clinicians who obtained parental or guardian consent for each patient and provided samples for xenografting. M.H. and M.D.N. were advisors on the project.

**ADDITIONAL INFORMATION**

Ethics approval and consent to participate All tumour specimens were obtained from patients at the Sydney Children’s Hospital Network (SCHN) under approval by the SCHN Human Research Ethics Committee (LNR/14/SCHN/392, LNR/14/SCHN/497). Informed parental or guardian consent was obtained for each patient. The study was performed in accordance with the Declaration of Helsinki.

Consent to publish All samples used in this study were de-identified. No personal information was exposed.

Data availability The data that support the findings of this study are available from the corresponding author upon reasonable request.

Competing interests The authors declare no competing interests.

**Funding information** This study was supported by the Kids Cancer Alliance, a Cancer Institute New South Wales Translational Cancer Research Centre (J.I.F., T.N.T.) and by Neuroblastoma Australia (J.I.F., T.N.T.).

Supplementary information is available for this article at https://doi.org/10.1038/s41416-019-0682-4.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**REFERENCES**

1. Kaatsch, P. Epidemiology of childhood cancer. Cancer Treat. Rev. 36, 277–285 (2010).

2. Matthay, K. K., Maris, J. M., Schliephacke, G., Nakagawara, A., Mackall, C. L., Diller, L. et al. Neuroblastoma. Nat. Rev. Dis. Primers 2, 16078 (2016).

3. Pinto, N. R., Applebaum, M. A., Volchenboum, S. L., Matthay, K. K., London, W. B., Ambros, P. F. et al. Advances in risk classification and treatment strategies for neuroblastoma. J. Clin. Oncol. 33, 3008–3017 (2015).

4. London, W. B., Bagatell, R., Weigel, B. J., Furtado, V., Abbruzzese, J. L., Kando, N., et al. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children’s Oncology Group early-phase trials. Cancer. 123, 4914–4923 (2017).

5. Cohen, L. E., Gordon, J. H., Popovsky, E. Y., Gunawardene, S., Duffey-Lind, E., Leimann, L. E. et al. Late effects in children treated with intensive multimodal therapy for high-risk neuroblastoma: high incidence of endocrine and growth problems. Bone Marrow Transplant. 49, 502–508 (2014).

6. Applebaum, M. A., Henderson, T. O., Lee, S. M., Pinto, N., Volchenboum, S. L. & Cohn, S. L. Second malignancies in patients with neuroblastoma: the effects of therapy studied in human neuroblastoma xenografts: relationship with tumour growth rate, chemotherapeutic sensitivities and levels of neuron-specific enolase. Exp. Cell Biol. 56, 277–284 (1988).

7. George, B. A., Yanik, G., Wells, R. J., Martin, L. W., Song, S., Ballard, E. T. et al. Growth patterns of human neuroblastoma xenografts and their relationship to treatment outcome. Cancer. 72, 3331–3339 (1993).

8. Braekevelt, N. & Sexell, D. Patient-derived xenografts as preclinical neuroblastoma models. Cell Tissue Res. 372, 233–243 (2018).

9. Braekevelt, N., van Stedingk, K., Fransson, I., Martinez-Monleon, A., Lindgren, D., Axelson, H. et al. Patient-derived xenograft models reveal intratumor heterogeneity and temporal stability in neuroblastoma. Cancer Res. 78, 5958–5969 (2018).

10. Braekevelt, N., Wigerup, C., Gisselsson, D., Mohlin, S., Mersielius, M., Beckman, S. et al. Neuroblastoma patient-derived orthotopic xenografts retain metastatic patterns and geno- and phenotypes of patient tumours. Int. J. Cancer. 136, E252–E261 (2015).

11. Braekevelt, N., Wigerup, C., Tadeo, I., Beckman, S., Sanden, C., Jonsson, J. et al. Neuroblastoma patient-derived orthotopic xenografts reflect the microenvironmental hallmarks of aggressive patient tumours. Cancer Lett. 375, 384–389 (2016).

12. Stewart, E., Federico, S. M., Chen, X., Shah, A. A., Bradley, C., Gordon, B. et al. Orthotopic patient-derived xenografts of paediatric solid tumours. Nature 549, 96–100 (2017).

13. Stewart, E., Shelat, A., Chen, X., Federico, S., Shaigamendjian, S. et al. Development and characterization of a human orthotopic neuroblastoma xenograft. Dev. Biol. 407, 344–355 (2015).

14. Van Noord, R. A., Thomas, T., Krook, M., Chukkapalli, S., Hoenerhoff, M. J., Dillman, D. et al. Establishment of a patient-derived orthotopic osteosarcoma mouse model. J. Transl. Med. 13, 166 (2015).

15. Hidalgo, M., Bruckheimer, E., Rajeshkumar, N. V., Garrido-Laguna, I., De Oliveira, E., Rubio-Viqueira, B. et al. A pilot clinical study of treatment guided by personalized tumorigrafts in patients with advanced cancer. Mol. Cancer Ther. 10, 1311–1316 (2011).

16. Kim, M. P., Evans, D. B., Wang, H., Abbuzzese, J. L., Fleming, J. B. & Gallick, G. E. Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat. Protoc. 4, 1670–1680 (2009).

17. Monsma, D. J., Monks, N. R., Cherka, D. M., Dylewski, D., Eustiger, E., Jahn, H. et al. Genomic characterization of explant tumourgraft models derived from fresh patient tumour tissue. J. Transl. Med. 10, 125 (2012).
36. Shultz, L. D., Lyons, B. L., Zurzonski, L. M., Gott, B., Chen, X., Chaleff, S. et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hematopoietic stem cells. *J. Immunol.* **174**, 6477–6489 (2005).

37. Ito, R., Katano, I., Kawai, K., Hirata, H., Ogura, T., Kamisako, T. et al. Highly sensitive model for xenogenic GVHD using severe immunodeficient NOG mice. *Transplantation* **87**, 1654–1658 (2009).

38. John, T., Yanagawa, N., Kohler, D., Craddock, K. J., Bandarchi-Chamkhaleh, B., Pintilie, M. et al. Characterization of lymphomas developing in immunodeficient mice implanted with primary human non-small cell lung cancer. *J. Thorac. Oncol.* **7**, 1101–1108 (2012).

39. Chen, K., Ahmed, S., Adeyi, O., Dick, J. E. & Ghanekar, A. Human solid tumor xenografts in immunodeficient mice are vulnerable to lymphomagenesis associated with Epstein-Barr virus. *PLoS One* **7**, e39294 (2012).

40. Zhang, L., Liu, Y., Wang, X., Tang, Z., Li, S., Hu, Y. et al. The extent of inflammatory infiltration in primary cancer tissues is associated with lymphomagenesis in immunodeficient mice. *Sci. Rep.* **5**, 9447 (2015).

41. Bondarenko, G., Ugolkov, A., Rohan, S., Kulesza, P., Dubrovskyi, O., Gursel, D. et al. Patient-derived tumor xenografts are susceptible to formation of human lymphocytic tumors. *Neoplasia* **17**, 735–741 (2015).

42. Wetterauer, C., Vlajnic, T., Schuler, J., Gsponer, J. R., Thalmann, G. N., Cecchini, M. et al. Early development of human lymphomas in a prostate cancer xenograft program using triple knock-out immunocompromised mice. *Prostate* **75**, 585–592 (2015).

43. Choi, Y. Y., Lee, J. E., Kim, H., Sim, M. H., Kim, K. K., Lee, G. et al. Establishment and characterisation of patient-derived xenografts as paraclinical models for gastric cancer. *Sci. Rep.* **6**, 22172 (2016).

44. Mukohyama, J., Iwakiri, D., Zen, Y., Mukohara, T., Minami, H., Kakeji, Y. et al. Evaluation of the risk of lymphomagenesis in xenografts by the PCR-based detection of EBV BamHI W region in patient cancer specimens. *Oncotarget* **7**, 50150–50160 (2016).

45. Thorley-Lawson, D. A. & Gross, A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. *N. Engl. J. Med.* **350**, 1328–1337 (2004).

46. Butler, K. A., Hou, X., Becker, M. A., Zanfagnin, V., Endersica-Gonzalez, S., Visscher, D. et al. Prevention of human lymphoproliferative tumor formation in ovarian cancer patient-derived xenografts. *Neoplasia* **19**, 628–636 (2017).

47. Byrne, F. L., McCarron, J. A. & Kavallaris, M. Analyses of tumor burden in vivo and metastasis ex vivo using luciferase-expressing cancer cells in an orthotopic mouse model of neuroblastoma. *Methods Mol. Biol.* **1372**, 61–77 (2016).

48. Teitz, T., Stanke, J. J., Federico, S., Bradley, C. L., Brennan, R., Zhang, J. et al. Preclinical models for neuroblastoma: establishing a baseline for treatment. *PLoS One* **6**, e19133 (2011).

49. Loh, A. H. P., Stewart, E., Bradley, C. L., Chen, X., Daryani, V., Stewart, C. F. et al. Combinatorial screening using orthotopic patient derived xenograft-expanded early phase cultures of osteosarcoma identify novel therapeutic drug combinations. *Cancer Lett.* **442**, 262–270 (2019).